Findings from the NELSON study, a population-based, controlled trial that enrolled 15,792 individuals, who were randomized 1:1 to either the study arm or control arm, demonstrated that the use of computed tomography (CT) screening among asymptomatic men at high risk for lung cancer led to a 26% (9-41%, 95% CI) reduction in lung cancer deaths at 10 years of study follow-up (at 86% compliance).
In the smaller subset of women, the rate-ratio of dying from lung cancer varied between 0.39 and 0.61 in different years of follow-up, indicating an even significant and larger reduction in lung cancer mortality than in men.
These results were presented during the 19th World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), in Toronto, Canada, by Harry J. De Koning, MD.,Ph.D., Erasmus MC, Rotterdam, The Netherlands.
“The purpose of early detection is to halt or delay adverse progression by offering treatment in an earlier stage than usual. But early detection and prevention at the population level does not guarantee effective prediction at the individual level, and we often need to implement programs for large groups of people, only some of whom will benefit,” De Koning said.
In this study participants were offered CT screenings at baseline, one, three and five and on e-half years after randomization. No screenings were offered to control arm participants. Participants’ records were linked to national registries with 100% coverage regarding cancer diagnosis (Netherlands Cancer Registry), date of death (Centre for Genealogy) and cause of death (Statistics Netherlands). An expert panel reviewed 65% of cases. The follow-up period comprised a minimum of 10 years, unless deceased, for 93.7% of enrolled participants.
The results of the study showed an 86% average CT screening compliance rate, encompassing 29,736 scans. In 9.3% of participants, additional CT scans were performed within two months to estimate nodule volume doubling time, leading to an overall referral rate of 2.3% for
suspicious nodules. Detection rates across the rounds varied between 0.8 and 1.1%, and 69% of screen-detected lung cancers were detected at Stage 1A or 1B.
A total of 261 lung cancers (52 interval cancers) were detected before the fourth round of follow ups
In a subset of analyzed patients, surgical treatment was three times significantly more prevalent in study lung cancer patients than in control arm patients (67.7 percent
versus 24.5, p<0.001).
“These findings show that CT screenings are an effective way to assess lung nodules in
people at high risk for lung cancer, often leading to detection of suspicious nodules and subsequent surgical intervention at relatively low rates and with few false positives, and can positively increase the chances of cure in this devastating disease,” De Koning said.
“It is the second largest trial in the world, with an even more favorable outcome than the first trial, the NLST, showed. These results should be used to inform and direct future CT screening in the world,” he concluded.
Last Editorial Review: September 26, 2018
Featured Image: Doctor examining lungs with x-ray film. Courtesy: © 2018 Fotolia. Used with permission.
Copyright © 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.